. Author manuscript; available in PMC: 2015 May 21.

Published in final edited form as: Cancer Cell Microenviron. 2015 Mar 16;2(1):e677. doi: 10.14800/ccm.677

Table 1.

Effects of Cabozantinib or Sunitinib on immune cell frequencies

Splenic	Control	Vaccine	Cabozantinib	Cabozantinib + Vaccine	Control	Vaccine	Sunitinib	Sunitinib > Vaccine
% CD4⁺ T cells	15.86 (0.36)	16.92 (1.20)^*	17.6 (2.48)	18.26 (1.16)^*	24.52 (2.38)	nd	20.32 (0.41)^*	nd
% CD8⁺ T cells	9.79 (1.20)	12.11 (2.15)^*	12.86 (2.04)^*	13.10 (1.31)^*	15.34 (2.54)	nd	18.26 (1.71)^*	nd
% Treg cells	1.18 (0.12)	1.18 (0.10)	0.98 (0.18)^*	1.11 (0.04)^*	2.04 (0.28)	nd	1.50 (0.09)^*	nd
% MDSCs	3.82 (0.18)	3.89 (0.70)	2.43 (0.28)^*	2.53 (0.22)^*	0.93 (0.24)	nd	0.37 (0.03)^*	nd

Intratumoral	Control	Vaccine	Cabozantinib	Cabozantinib + Vaccine	Control	Vaccine	Sunitinib	Sunitinib > Vaccine
% CD4⁺ T cells	0.03	0.75^*	0.46^*	1.13^*	3.86 (3.28)	3.41 (2.94)	2.03 (0.75)	1.90 (0.86)
% CD8⁺ T cells	0.03	1.10^*	0.22^*	1.49^*	0.32 (0.12)	0.46 (0.22)	0.69 (0.22)^*	0.66 (0.03)^*
% Treg cells	0.01	0.09^*	0.13^*	0.24^*	0.11 (0.06)	0.07 (0.02)^*	0.07 (0.02)^*	0.05 (0.02)^*
% MDSCs	0.02	0.61^*	0.21^*	0.46^*	1.48 (0.23)	1.35 (0.99)	1.16 (0.46)	0.48 (0.13)^*

Flow cytometric analysis of splenic immune cell subsets or tumor infiltrating lymphocytes in MC38-CEA tumors. Cabozantinib and vaccine were administered 14 days post tumor implantation. Tumors were 28 days post tumor implantation. Sunitinib was administered 7 days post tumor vaccination and in this case vaccine was administered 14 days post tumor implantation. Tumors were 21 days post tumor implantation. Splenic studies, n = 5 mice/group. Intratumoral studies, cabozantinib, n = 2 mice/group; sunitinib, n = 12-17 mice/group.

= p<0.01 as determined by Student’s t test or the Kolmogorov-Smirnov test, nd = not determined